
GM of Organ Health at Natera, Bernie Tobin Discusses Evolving Transplant Diagnostic Market
Bernie Tobin, the GM of Organ Health at Natera discusses the evolving landscape of cell free DNA testing in organ transplantation. Topics discussed include the science behind cell free DNA testing in transplant diagnostics and how that science has evolved, the evolution of testing protocols for organ transplant centers and how this has impacted the market for cell free DNA tests, differentiation versus market competitors CareDx and Eurofins Viacor, the U.S. and international markets and how they are evolving, recent guideline changes including the ISHLT guidelines in heart transplant, new data generation including the Trifecta and Proactive studies and their impact on the market/reimbursement, recent Medicare billing article changes and the new proposed LCD from Palmetto for organ transplant testing including how the industry is responding to these changes and lobbying against new restrictive measures in these updates, Renasight and genetic testing for kidney disease including the clinical applications and market, and the evolution of the industry over the next five years.